Prosecution Insights
Last updated: November 18, 2026
Application No. 18/263,637

SOLUBLE CHELATOR FOR TARGETING RECOMBINANT PROTEINS

Non-Final OA §102§103§112
Filed
Jul 31, 2023
Priority
Feb 02, 2021 — provisional 63/144,907 +1 more
Examiner
HOU, FRANK S
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cube Biotech GmbH
OA Round
3 (Non-Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
99 granted / 146 resolved
+7.8% vs TC avg
Strong +36% interview lift
Without
With
+36.1%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
36 currently pending
Career history
183
Total Applications
across all art units

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 9-26 of R. Fabis, et al., US 18/263,637 (07/31/2023) are pending. Claims 10-17 are withdrawn as drawn to non-elected Groups IV-XI. Claims 9 and 18-26 under examination on merits. Claims 9, 18-21 and 23-24 are rejected, claims 9, 22-23 and 25-26 are objected to. Election/Restrictions Pursuant to the restriction requirement, Applicant elected Group III (claim 9), with traverse, in the reply filed on 02/10/2026. Claims 1-8 and 10-17 drawn to non-elected are withdrawn from consideration pursuant to 37 CFR 1.142(b). Applicant cancelled claims 1-8, amended claim 9 and added new claims 18-26 falling within the scope of the amended claim 9, in the reply filed on 06/22/2026. The Restriction Requirement is maintained as Final. Withdrawn Claim Rejections- 35 U.S.C. 112(b) Rejection of claims 9 under 35 U.S.C. 112(b) as indefinite in view of claim amendment and/or applicant’s argument is persuasive. Claim Objections Claim 23 is objected to on the grounds of improper parenthetical. While Applicant may intend that the parenthetical phrase adds clarification, it is at best superfluous and better practice is to amend so as to remove the parentheticals to avoid confusion as to whether Applicant improperly intends preferences within the claim. See MPEP § 2173.05(d). Correction of all such parenthetical throughout the claims is required. Claims 22 and 25-26 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 9, 18-19 and 23 are rejected under 35 U.S.C. 102(a)(1)as being anticipated by Cube Biotech GMBH, WO2017046625A1 (2017)(“Cube”). Cube teaches a multimeric chelator, these chelators are polycarboxylates, such as EDTA, DTPA, and the like, and they are connected via linkers, forming chains, the chelator chains can be bound to a solid phase via an ester-, thioester- or amide group of one terminal chelator. Cube at Abstract. Cue teaches examples of the multimeric chelator, such as Example 5 chelator of EDTA-EDA-EDTA which is prepared by a reaction of ethylene diamine (1.67 mmol) with EDTA dianhydride (3.33 mmol). Cue at page 12, Example 5, Synthesis of EDTA-EDA-EDTA. Thus, the EDTA-EDA-EDTA has a chemical structure as indicated below. PNG media_image1.png 624 1023 media_image1.png Greyscale The multimeric chelator EDTA-EDA-EDTA maps the Formula IV in the instant claim 9 as: R1 is EDTA that is a chelating carboxylic acid and R 3 is H; Which meets each and every limitation of the structure requirement of the Formula IV in the instant claim 9 and 23. Regarding the solubility, the same compound would has the same properties including the solubility in the same solvent. Where the claimed and prior art products are identical or substantially identical in composition to a claimed composition, a prima facie case of either anticipation or obviousness has been established subject to Applicant’s rebuttal. MPEP § 2112.01(I) (citing In re Ludtke, 441 F.2d 660, 169 USPQ 563 (CCPA 1971) (holding that a prior art structure anticipated a claimed structure even though a claimed functional recitation was not specifically taught in the prior art reference because applicant had failed to show that the prior art did not possess the functional characteristics of the claims)). Cue teaches to couple the synthesized multimeric chelator EDTA-EDA-EDTA on a solid phase that is amine agarose. Cue at page 13, paragraph 1-2, Example 5. Per Example 12, Cue also teaches to use the solid phase bound multimeric chelator EDTA-EDA-EDTA to purify a His-tagged GFP (green fluorescent protein) and teaches that the solid phase bound multimeric chelator EDTA-EDA-EDTA has a protein binding capacity of 84 mg/ml. Cue at page 16, Example 12, Purification of 6xhis-GFP with aminopolycarboxylic acid resins. Thus, Cue teaches a modified multimeric chelator EDTA-EDA-EDTA that comprise a His-tag, which meet each and every limitation of claims 9 and 23, therefore, claims 9 and 23 are anticipated. Claim 18 is anticipated because the R1 in the Cue modified multimeric chelator EDTA-EDA-EDTA that comprise a His-tag has the follows structure: PNG media_image2.png 453 447 media_image2.png Greyscale Which maps the formula II in claims 18 as n is 2. Claim 19 is anticipated because the above mentioned Cue modified multimeric chelator EDTA-EDA-EDTA comprise a His-tag. Applicant’s Argument Applicant argues the on the ground that claim 9 structurally differs from Cube at least in that some nitrogen atoms are replaced by oxygen atoms and Cube the ligand is bound to a solid phase whereas according to the present invention a soluble ligand is defined. Response to claim rejection under section 102 at page 10 of the Remarks filed on 06/22/2026. These arguments have been fully considered but not persuasive. As detail discussed in the 102 rejection above that the Cube multimeric chelator EDTA-EDA-EDTA meets each and every limitation of the Formula IV in the instant claim 9, there is no issue of replacing some nitrogen atoms by oxygen atoms as Applicant argues. Further, the instant claim 9 does not require the claimed tag modified chelator is soluble. Applicant argues something that is not be claimed. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 20-21 and 24 are rejected under 35 U.S.C. 103 as being unpatentable over Cube Biotech GMBH, WO2017046625A1(2017)(“Cube”) as applied above for the rejection of claim 9. Cube Biotech GMBH, WO2017046625A1 (2017)(“Cube”). Cube teaches a solid-phase bound multimeric chelator, where one aminopolycarboxylic acid is coupled to the solid phase via one carboxylic group and connected to other aminocarboxylic acids via di- or trifunctional linkers; and the chelator bound to the solid phase has the following formula: PNG media_image3.png 76 551 media_image3.png Greyscale Cube at page 5, line 10-14. Cube also teaches that: Examples for trifunctional linkers are trialkoxylated glycerol, triethanolamine, tris(3-aminopropyl)-amine, tris(2-aminoethyl)amine, diethylenetriamine. Cube at page 7, the last second paragraph, emphasis added. Thus, Cube teaches one ordinary skill in the art that triethanolamine and tris(2-aminoethyl)amine are alternative for trifunctional linkers in Cube solid-phase bound multimeric chelators. Cube teaches that after coupling of the chelator chains with a solid phase, the reaction product can be charged with metal ions, which can bind the desired target proteins. As Ni, Cu, Co, Zn, Fe, Eu, Sc are suitable for reversible protein binding, nickel and cobalt are preferred for purification of his-tagged proteins, while iron and alumina are preferred for the isolation of phosphoproteins. Cube at page 8, paragraph 2, line 1-6, emphasis added. Cube teaches examples of the multimeric chelator, such as Example 5 chelator of EDTA-EDA-EDTA that meets each and every limitation of the formula IV in the instant claim 9 and Cube also teaches one modified multimeric chelator EDTA-EDA-EDTA comprising one his-tag, which meets each and every limitation of claim 9 as discussed above. In addition to solid-phase bound EDTA-EDA-EDTA in the Example 5, Cube also teaches other solid-phase bound multimeric chelator such as EDTA-EDA-EDTA-EDA-EDTA-agarose in the Example 7 and trimeric EDTA (EDTA-triethanolamine -EDTA) in Example 8, which are emphasized in claim 22. Cube Examples 7-8 at page 13-14 and Claim 22. PNG media_image4.png 1089 1080 media_image4.png Greyscale Difference between Cue and Claims 20-21, 24 The Cube modified multimeric chelator EDTA-EDA-EDTA comprising one His-tag differs from claim 20 in that it does not further comprise a positively charged metal-ion selected from the metals Ni, Co, Cu, Fe, Ca, Zn, Al, Eu, Ga, and Sc. The Cube modified multimeric chelator EDTA-EDA-EDTA comprising one His-tag differs from claim 21 in that EDTA-EDA-EDTA does not comprise 8 or more of carboxy groups. The Cube modified multimeric chelator EDTA-EDA-EDTA comprising one His-tag differs from claim 24 in that EDTA-EDA-EDTA does not have a structure of the Formula VI. Obviousness Rationales of Claims 20-21 and 24 Claim 20 is obvious because one ordinary skill in the art seeking chelator having higher binding capacity for a His-tagged GFP is motivated to bind nickel and/or cobalt ion with the Cube example 5 solid-phase bound EDTA-EDA-EDTA, and then use the nickel and/or cobalt ion charged solid-phase bound EDTA-EDA-EDTA to purify the his-tagged GFP, thus arrive at a modified multimeric chelator meeting each and every limitation of claim 20, therefore, claim 20 is obvious. One ordinary skill has a motivation to do so with a reasonable expectation of success because Cube teaches that his solid-phase bound chelator can be charged with metal ions such as nickel and cobalt, which are preferred for purification of his-tagged proteins. Cube at page 8, paragraph 2, line 1-6. Claim 21 is obvious because one ordinary skill in the art seeking chelator having higher binding capacity for a His-tagged GFP is motivated to conduct the Cube Example 12 by replacing the solid-phase bound EDTA-EDA-EDTA (Example 5 product) with the solid-phase bound EDTA-EDA-EDTA-EDA-EDTA, thus arrive at a solid-phase bound EDTA-EDA-EDTA-EDA-EDTA comprising a His-tagged protein, which meets each and every limitation of claim 21 as EDTA-EDA-EDTA-EDA-EDTA comprise 8 carboxy groups. One ordinary skill has a motivation to do so with a reasonable expectation of success because solid-phase bound EDTA-EDA-EDTA-EDA-EDTA has more chelator groups than those of the solid-phase bound EDTA-EDA-EDTA. Regarding claim 24, one ordinary skill in the art seeking stable chelator having higher binding capacity is motivated to (i). replace the triethanolamine in the Example 8 EDTA-triethanolamine -EDTA with tris(2-aminoethyl)amine, (ii) bind the modified product with amino agarose, and (iii)use the agarose-bound product to conduct the Cube Example 12 for his-tagged GFP purification, thus arrive at a product meeting each and every limitation of claim 24, therefore, claim 24 is obvious. PNG media_image5.png 2441 3331 media_image5.png Greyscale One ordinary skill has a motivation to do so with a reasonable expectation of success because: (i). Cube teaches that triethanolamine and tris(2-aminoethyl)amine are alternative for trifunctional linkers in Cube solid-phase bound multimeric chelator; (ii). replacing triethanolamine with tris(2-aminoethyl)amine can switch the three ester groups in the Example 8 EDTA-triethanolamine-EDTA into three amide group, thus increase stability of the solid-phase bound multimeric chelator as amides require much harsher conditions to hydrolyses than its ester homologue1; and (iii). replacing the solid-phase bound EDTA-EDA-EDTA (Example 5 product) with the proposed solid-phase bound trimeric EDTA-tris(2-aminoethyl)amine-EDTA can increase binding capacity as it has 4 more chelator group than the solid-phase bound EDTA-EDA-EDTA. Applicant’s Argument Applicant argues on the ground that one ordinary skill is not motivated to modify the Cube chelator by replacing nitrogen atoms with oxygen: First, by replacing nitrogen atoms with oxygen atoms, new compound classes are created, which can have totally different properties. It would not have been possible to predict which properties the new classes of compounds would have. That means, it cannot be concluded that replacing oxygen atoms with nitrogen atoms and vice versa that compounds having similar and comparable properties are provided. It is even not possible to predict, which properties the new compounds have at all. That is, the skilled person has not the slightest motivation to replace one atom by a different atom, like in the present case oxygen by nitrogen or vice versa since there is no reasonable expectation of success in the sense of obtaining the required properties. Paragraph 1-3 at page 11 of the Remarks filed on 06/22/2022. This argument has been fully considered but not persuasive because as mentioned in the rejection above that Cube teaches that triethanolamine and tris(2-aminoethyl)amine are alternative for trifunctional linkers in Cube solid-phase bound multimeric chelator, therefore, there is a reasonable expectation of success by replacing triethanolamine with tris(2-aminoethyl)amine; further, the proposed replacement also can increase stability of the solid-phase bound chelator. Therefore, one ordinary skill in the art is motivated to do the proposed replacement. Subject Matter Free of the Art Claims 22 and 25-26 are free of the art recorded. The closest prior art of record Biotech GMBH, WO2017046625A1 (2017)(“Cube”). Biotech GMBH, WO2017046625A1 (2017)(“Cube”) As detail discussed in the 102 rejection above that Cube teaches a chelator meeting each and every limitation of claim 9. Difference Between Cube and Claims 22 and 25-26 The Cube chelator differs from claim 22 in that EDTA-EDA-EDTA does not comprise 6 or more amino groups2. The Cube chelator differs from claims 25-26 in that EDTA-EDA-EDTA does not comprise the claimed chemical structures. Claims 22 and 25-26 are Not Obvious Claims 22 and 25-26 are not obvious because neither Cube NOR Cube in view a second art to motive one ordinary skill in the art to modify the Cube chelator to arrive at the claimed chelator. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to FRANK S. HOU whose telephone number is (571)272-1802. The examiner can normally be reached 6:30 am-2:30 pm Eastern on Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at (571)2705241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /FRANK S. HOU/Examiner, Art Unit 1692 /ALEXANDER R PAGANO/Primary Examiner, Art Unit 1692 1 See the attached information disclosed on the web of Chemistry Stack Exchange-2020. 2 The specification defines amino group as -NH2. See specification at page 4, line 19-20.
Read full office action

Prosecution Timeline

Jul 31, 2023
Application Filed
Mar 23, 2026
Non-Final Rejection mailed — §102, §103, §112
Jun 22, 2026
Response Filed
Aug 13, 2026
Final Rejection mailed — §102, §103, §112
Sep 30, 2026
Response after Non-Final Action
Oct 08, 2026
Request for Continued Examination
Oct 11, 2026
Response after Non-Final Action
Nov 12, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12790357
Metal Halide Perovskites, Light-Emitting Diodes, and Methods
2y 2m to grant Granted Nov 10, 2026
Patent 12780860
NEW CYCLOPENTADIENYL LIGANDS FOR IRON CATALYSIS
3y 2m to grant Granted Nov 03, 2026
Patent 12774295
DEUTERATED ORGANOTIN COMPOUNDS, METHODS OF SYNTHESIS AND RADIATION PATTERNING
4y 8m to grant Granted Oct 27, 2026
Patent 12767680
LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND
3y 2m to grant Granted Oct 20, 2026
Patent 12759887
ORGANOSILICON PRECURSORS FOR DEPOSITION OF SILICON-CONTAINING FILMS
4y 10m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+36.1%)
High
PTA Risk
Based on 146 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month